Abstract:
:Oseltamivir is the ethyl ester prodrug of the antiviral molecule, oseltamivir carboxylate, a potent and selective inhibitor of influenza A and B neuraminidase (NA) (sialidase). It is highly bioavailable in capsule and suspension formulations and, after conversion to the active metabolite in the liver, distributes throughout the body, including the upper and lower respiratory tract. Oseltamivir carboxylate is 3% bound to human plasma proteins and eliminated through the kidneys by a first-order process as unchanged drug by glomerular filtration and tubular secretion by an anionic transporter system. Given these characteristics, its potential for adverse interactions with other drugs appears limited to those arising from competitive inhibition of excretion by the renal tubular epithelial cell anionic transporter. The terminal plasma elimination half-life is 1.8 h in healthy adults. Renal clearance is inversely related to renal function and averages 23 h after oral administration in individuals with creatinine clearance < 30 ml/min. In vitro studies have demonstrated potent antiviral activity against all strains of influenza A and B tested including avian H5N1 and H9N2 strains recently implicated in human cases in Hong Kong. Studies of both experimental and naturally-occurring influenza in humans have demonstrated efficacy in both the prevention and treatment of influenza A and B infection. The drug is well-tolerated with the only clinically important side effect being mild gastrointestinal upset. Resistance has been uncommonly seen after clinical use; the highest incidence was 5.5% in children treated for influenza A infection for 5 days. Viruses that develop resistance appear to be less virulent in laboratory animals and to replicate less efficiently than parent strains. Although oseltamivir and the M2 ion channel inhibitors, amantadine and rimantadine, have not been directly compared in clinical trials, the greater breadth of spectrum of oseltamivir, its modest side effect profile compared to amantadine and its lesser propensity to engender the emergence of transmissible drug-resistant strains all suggest strongly that oseltamivir is a significant new agent for the prevention and treatment of influenza. A series of controlled trials comparing M2 ion channel inhibitor drugs and the new neuraminidase (NA) inhibitor agents are now needed to test this hypothesis and thereby to further advance the science of antiviral drug use to control influenza.
journal_name
Expert Opin Pharmacotherjournal_title
Expert opinion on pharmacotherapyauthors
Doucette KE,Aoki FYdoi
10.1517/14656566.2.10.1671keywords:
subject
Has Abstractpub_date
2001-10-01 00:00:00pages
1671-83issue
10eissn
1465-6566issn
1744-7666journal_volume
2pub_type
杂志文章,评审abstract::The incidence of nucleoside analogue-related lactic acidosis has been estimated in 0.57 - 8.5 cases/1000 person years of antiretroviral therapy. The onset of lactic acidosis is usually insidious and patients complain of nausea, vomiting, abdominal pain, fatigue and weight loss. When lactate levels are high enough, a c...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.4.8.1321
更新日期:2003-08-01 00:00:00
abstract::The burden of insomnia has had a significant effect not only on the socioeconomic matrix, but also the medical terrain, as signified by the increased morbidity and mortality of its associated psychiatric and organic sequelae. To this end, a plethora of pharmacotherapeutic agents have been recently introduced that addr...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.7.13.1731
更新日期:2006-09-01 00:00:00
abstract:OBJECTIVE:Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus erythematosus (SLE). MMF and EC-MPS pharmacokinetics were examined to devise guidance for therapeutic drug monitoring (TDM) for SLE patients with normal ren...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656561003592144
更新日期:2010-04-01 00:00:00
abstract:INTRODUCTION:Miconazole (MCZ) is a time-honored antifungal of the imidazole class. MCZ exerts a multipronged effect on fungi. It inhibits the cytochrome P450 complex, including the 14α-demethylase enzyme required for ergosterol biosynthesis, in fungal cell membranes. In addition, intracellular accumulation of toxic met...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2012.687047
更新日期:2012-06-01 00:00:00
abstract:INTRODUCTION:Diabetic foot ulcers, especially when they become infected, are a leading cause of morbidity and may lead to severe consequences, such as amputation. Optimal treatment of these diabetic foot problems usually requires a multidisciplinary approach, typically including wound debridement, pressure off-loading,...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2015.1021780
更新日期:2015-04-01 00:00:00
abstract::Venous thromboembolism is a frequent, life-threatening, postoperative complication of hip-fracture and total-knee-replacement surgery. Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation. Low molecular weight heparins, such as enoxapa...
journal_title:Expert opinion on pharmacotherapy
pub_type: 评论,杂志文章,评审
doi:10.1517/14656566.3.4.455
更新日期:2002-04-01 00:00:00
abstract::Elevated blood pressure levels are highly prevalent and are a major reason for cardiovascular events and thus place a significant financial burden on healthcare systems worldwide. Guidelines recommend five first-line anti-hypertensive drug classes, but compelling indications may indicate favoring one drug class over a...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656560903103820
更新日期:2009-08-01 00:00:00
abstract::There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commissio...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2.1.75
更新日期:2001-01-01 00:00:00
abstract:BACKGROUND:Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive breast cancer. OBJECTIVE:To determine whether the aromatase inhibitor anastrozole should replace tamoxifen as the adjuvant treatment in this cancer. METHODS:Two recent trials of anastrozole and tamoxifen as adju...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.9.9.1619
更新日期:2008-06-01 00:00:00
abstract::Neonates in the neonatal intensive care unit experience hundreds of painful procedures at a time of rapid neurological development. Although the immediate responses to pain may be protective, the potential long-term effects of early and under-treated pain are concerning. As pain assessment is the first step in the pro...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.4.4.475
更新日期:2003-04-01 00:00:00
abstract:INTRODUCTION:Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2013.802774
更新日期:2013-08-01 00:00:00
abstract:INTRODUCTION:Paget's disease of the bone is a common condition in some populations, affecting almost 10% of older adults in western Europe. Though frequently asymptomatic, it can sometimes result in severe disabilities. Timely intervention is now able to arrest disease progression in the majority of patients. AREAS CO...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2012.662486
更新日期:2012-04-01 00:00:00
abstract:INTRODUCTION:Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2012.644787
更新日期:2012-02-01 00:00:00
abstract:INTRODUCTION:Bipolar disorder is characterized by mood instability, which can be challenging to manage. First-line pharmacological approaches usually involve lithium, anticonvulsants and antipsychotics. Over the past fifteen years, several second-generation antipsychotics have demonstrated benefits for various phases o...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.2012.681377
更新日期:2012-08-01 00:00:00
abstract:INTRODUCTION:Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 ( Dymista ) is a novel intranasal formulatio...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2013.828693
更新日期:2013-10-01 00:00:00
abstract:BACKGROUND:Dexmethylphenidate is a single-isomer stimulant medication approved for the treatment of attention deficit hyperactivity disorder (ADHD). Single-isomer drugs have the potential for decreased undesired effects and improved therapeutic efficacy. Stimulant medications have been the mainstay treatments for ADHD ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656560903386284
更新日期:2009-11-01 00:00:00
abstract:INTRODUCTION:Epileptic emergencies are frequently encountered and include ictal events as status epilepticus or seizure clusters, and non-ictal situations like postictal psychosis or acute drug side effects. The aim of this review was to describe recent pharmacological advances in the treatment of epileptic emergencies...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2016.1241236
更新日期:2016-11-01 00:00:00
abstract:INTRODUCTION:Bipolar I disorder (BD I) is complex with a chronic course that significantly impacts a sufferer's quality of life. As of right now, there are many available treatments that aim to rapidly treat manic or depressive episodes and stabilize mood. The purpose of this report is to provide an up-to-date comprehe...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2018.1426746
更新日期:2018-02-01 00:00:00
abstract:INTRODUCTION:Peripheral artery disease (PAD) is a prevalent but underdiagnosed manifestation of atherosclerosis that has a worse prognosis than coronary artery disease. Patients with PAD are at heightened risk of both systemic cardiovascular adverse events and limb-related morbidity. There is insufficient awareness of ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2020.1774556
更新日期:2020-09-01 00:00:00
abstract:INTRODUCTION:Aripiprazole long acting once-monthly (AOM) is approved for the treatment of schizophrenia in adults. Despite recent evidence of AOM efficacy in the acute treatment of schizophrenia, it is recommended that AOM should be started once the acute symptoms are controlled and patients are stabilized. However, th...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2016.1244526
更新日期:2016-11-01 00:00:00
abstract::Introduction: Multiple sclerosis (MS) is a demyelinating disease, causing axonal damage and disability. Dalfampridine (DAL) is an extended-release formulation of 4-aminopyridine (4AP) and broad-spectrum voltage-dependent potassium channel blocker that is reported to improve motor, visual and cognitive functions. Furth...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2019.1623879
更新日期:2019-08-01 00:00:00
abstract:INTRODUCTION:Treating acute myeloid leukemia (AML) in older adults remains daunting. The unique biology often renders conventional chemotherapies less effective. Accurately predicting the toxicities of treatment is another unresolved challenge. Treatment planning thus requires a good knowledge of the current trial data...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2018.1465562
更新日期:2018-06-01 00:00:00
abstract::This paper describes the functional roles of the closely related pharmacogenetic and pharmacogenomic sciences in medicine. Firstly, they provide means for a better understanding of the function of drugs, and particularly of the differences of drug action between individuals and also between racially categorised popula...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.6.8.1299
更新日期:2005-07-01 00:00:00
abstract::Non-motor symptoms may considerably reduce parkinsonian quality of life, particularly in advanced stages of the disease. Autonomic features, such as seborrhoea, hyperhidrosis, orthostatic hypotension, excessive salivation, bladder dysfunction and GI disturbances, and neuropsychiatric symptoms, such as depression, slee...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.3.4.381
更新日期:2002-04-01 00:00:00
abstract:INTRODUCTION:Patisiran and inotersen are two therapies approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, a rapidly progressive disease with a substantial clinical burden. This analysis indirectly compares the efficacy of patisiran and inotersen on neuropathy and qu...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2020.1811850
更新日期:2021-01-01 00:00:00
abstract:OBJECTIVES:In 1991, small cell lung cancer (SCLC) was reported as the first tumour type where colony stimulating factor (CSF) support was clinically effective. We reviewed 13 health services research studies that addressed CSF use as supportive care for SCLC. METHODS:Findings from American Society of Clinical Oncology...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.3.9.1273
更新日期:2002-09-01 00:00:00
abstract:BACKGROUND:Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome. OBJECTIVE:The aim of this study was to review the preclinical and clinical data on fesoterodine. METHODS:The study involved a search of the Medline database and the proceedings volumes of urological congresses. RESULTS...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.9.10.1787
更新日期:2008-07-01 00:00:00
abstract:INTRODUCTION:In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future. AREAS COVERED:Recent (post 2013) phase III clinical trials of schizophrenia-targeted the...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2016.1149164
更新日期:2016-01-01 00:00:00
abstract:INTRODUCTION:Dementia with Lewy bodies (DLB) has no approved symptomatic or disease-modifying treatments in the US and Europe, despite being the second most common cause of neurodegenerative dementia. AREAS COVERED:Herein, the authors briefly review the DLB drug development pipeline, providing a summary of the current...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2020.1828350
更新日期:2020-10-06 00:00:00
abstract::Motor fluctuations are a common problem in the long-term management of Parkinson's disease (PD), resulting in disability and impaired quality of life. The relatively short serum half-life (approximately 90 min) of oral levodopa/carbidopa and its erratic absorption due to delayed and inconsistent gastric emptying (a no...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.8.5.657
更新日期:2007-04-01 00:00:00